New cGMP fermentation facility in the UK set to meet growing demand for drug substance production, supporting biopharma ...
The interim phase 2 trial results show a good immune response in participants and the therapy is well tolerated to date.
The Series D financing will support the clinical development of two ADCs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback